These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35096128)

  • 1. Dapagliflozin Ameliorates STZ-Induced Cardiac Hypertrophy in Type 2 Diabetic Rats by Inhibiting the Calpain-1 Expression and Nuclear Transfer of NF-
    Liu L; Luo H; Liang Y; Tang J; Shu Y
    Comput Math Methods Med; 2022; 2022():3293054. PubMed ID: 35096128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simvastatin Improves Cardiac Hypertrophy in Diabetic Rats by Attenuation of Oxidative Stress and Inflammation Induced by Calpain-1-Mediated Activation of Nuclear Factor-κB (NF-κB).
    Han Q; Liu Q; Zhang H; Lu M; Wang H; Tang F; Zhang Y
    Med Sci Monit; 2019 Feb; 25():1232-1241. PubMed ID: 30767945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF-β/Smad signalling in type 2 diabetic rats.
    Tian J; Zhang M; Suo M; Liu D; Wang X; Liu M; Pan J; Jin T; An F
    J Cell Mol Med; 2021 Aug; 25(16):7642-7659. PubMed ID: 34169635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of extracellular matrix stiffness on efficacy of Dapagliflozin for diabetic cardiomyopathy.
    Zhu T; Ye Z; Song J; Zhang J; Zhao Y; Xu F; Wang J; Huang X; Gao B; Li F
    Cardiovasc Diabetol; 2024 Jul; 23(1):273. PubMed ID: 39049086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Dapagliflozin and Liraglutide on Diabetes-Induced Cardiomyopathy in Rats: Implication of Oxidative Stress, Inflammation, and Apoptosis.
    El-Shafey M; El-Agawy MSE; Eldosoky M; Ebrahim HA; Elsherbini DMA; El-Sherbiny M; Asseri SM; Elsherbiny NM
    Front Endocrinol (Lausanne); 2022; 13():862394. PubMed ID: 35370937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench.
    Shih JY; Lin YW; Fisch S; Cheng JT; Kang NW; Hong CS; Chen ZC; Chang WT
    Diabetes; 2021 Jan; 70(1):262-267. PubMed ID: 33115828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
    Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
    Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
    Ye Y; Bajaj M; Yang HC; Perez-Polo JR; Birnbaum Y
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):119-132. PubMed ID: 28447181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation.
    Hazem RM; Ibrahim AZ; Ali DA; Moustafa YM
    Int Immunopharmacol; 2022 Mar; 104():108503. PubMed ID: 34998036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling.
    Zhang Y; Lin X; Chu Y; Chen X; Du H; Zhang H; Xu C; Xie H; Ruan Q; Lin J; Liu J; Zeng J; Ma K; Chai D
    Cardiovasc Diabetol; 2021 Jun; 20(1):121. PubMed ID: 34116674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin attenuates diabetic cardiomyopathy through erythropoietin up-regulation of AKT/JAK/MAPK pathways in streptozotocin-induced diabetic rats.
    El-Sayed N; Mostafa YM; AboGresha NM; Ahmed AAM; Mahmoud IZ; El-Sayed NM
    Chem Biol Interact; 2021 Sep; 347():109617. PubMed ID: 34391751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of NF-κB and Wnt/β-catenin/GSK3β Signaling Pathways Ameliorates Cardiomyocyte Hypertrophy and Fibrosis in Streptozotocin (STZ)-induced Type 1 Diabetic Rats.
    Liu JJ; Shentu LM; Ma N; Wang LY; Zhang GM; Sun Y; Wang Y; Li J; Mu YL
    Curr Med Sci; 2020 Feb; 40(1):35-47. PubMed ID: 32166663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
    Birnbaum Y; Bajaj M; Yang HC; Ye Y
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapagliflozin reduces the amplitude of shortening and Ca(2+) transient in ventricular myocytes from streptozotocin-induced diabetic rats.
    Hamouda NN; Sydorenko V; Qureshi MA; Alkaabi JM; Oz M; Howarth FC
    Mol Cell Biochem; 2015 Feb; 400(1-2):57-68. PubMed ID: 25351341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted inhibition of calpain reduces myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes.
    Li Y; Ma J; Zhu H; Singh M; Hill D; Greer PA; Arnold JM; Abel ED; Peng T
    Diabetes; 2011 Nov; 60(11):2985-94. PubMed ID: 21911754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin elevates plasma high-density lipoprotein levels and influences visceral fat gene expression in streptozotocin-induced diabetes mellitus.
    Kralova E; Marusakova M; Hadova K; Krenek P; Klimas J
    J Pharm Pharmacol; 2021 Apr; 73(6):778-784. PubMed ID: 33749792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes.
    Hodrea J; Saeed A; Molnar A; Fintha A; Barczi A; Wagner LJ; Szabo AJ; Fekete A; Balogh DB
    PLoS One; 2022; 17(2):e0263285. PubMed ID: 35176041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bamboo leaf extract ameliorates cardiac fibrosis possibly via alleviating inflammation, oxidative stress and apoptosis.
    Zhang L; Mao Y; Pan J; Wang S; Chen L; Xiang J
    Biomed Pharmacother; 2017 Nov; 95():808-817. PubMed ID: 28892792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Empagliflozin inhibits inflammatory response and alleviates renal injury in type 2 diabetic rats by up-regulating the expression of exchange protein 1 directly activated by cAMP (Epac1)].
    Qian Y; Wan L; Lu Y; Ni W; Yang H; Pan Y; Chen W
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Feb; 40(2):129-134. PubMed ID: 38284253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-20a-5p overexpression prevented diabetic cardiomyopathy via inhibition of cardiomyocyte apoptosis, hypertrophy, fibrosis and JNK/NF-κB signalling pathway.
    Liu X; Guo B; Zhang W; Ma B; Li Y
    J Biochem; 2021 Oct; 170(3):349-362. PubMed ID: 33837411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.